APO Research
Talk to an analyst

APO RESEARCH · REPORT

Proliferative Vitreoretinopathy (PVR) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchProliferative Vitreoretinopathy (PVR) Therapeutics Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Proliferative Vitreoretinopathy (PVR) Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Proliferative Vitreoretinopathy (PVR) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Proliferative Vitreoretinopathy (PVR) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Proliferative Vitreoretinopathy (PVR) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Proliferative Vitreoretinopathy (PVR) Therapeutics market include Novartis AG, RXi Pharmaceuticals Corp and Promedior Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Proliferative Vitreoretinopathy (PVR) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Proliferative Vitreoretinopathy (PVR) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Company

Novartis AG

RXi Pharmaceuticals Corp

Promedior Inc

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Type

PRM-167

XOMA-089

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Application

Clinic

Hospital

ASCs

Others

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Proliferative Vitreoretinopathy (PVR) Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Proliferative Vitreoretinopathy (PVR) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Proliferative Vitreoretinopathy (PVR) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Proliferative Vitreoretinopathy (PVR) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proliferative Vitreoretinopathy (PVR) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proliferative Vitreoretinopathy (PVR) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Proliferative Vitreoretinopathy (PVR) Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Proliferative Vitreoretinopathy (PVR) Therapeutics industry.

Chapter 3: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Proliferative Vitreoretinopathy (PVR) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Proliferative Vitreoretinopathy (PVR) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends Table 2. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers Table 3. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges Table 4. Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints Table 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Company (k units) & (2021-2026) Table 8. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price (US$/unit) of Company (2021-2026) Table 10. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company, Product Type & Application Table 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PRM-167 Table 18. Significant Companies of XOMA-089 Table 19. Significant Companies of Others Table 20. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type (2021-2026) & (k units) Table 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type (2027-2032) & (k units) Table 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Type (2021-2026) Table 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Type (2027-2032) Table 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type (2021-2026) Table 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinic Table 31. Significant Companies of Hospital Table 32. Significant Companies of ASCs Table 33. Significant Companies of Others Table 34. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application (2021-2026) & (k units) Table 36. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application (2027-2032) & (k units) Table 37. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Application (2021-2026) Table 38. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Application (2027-2032) Table 39. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application (2021-2026) Table 43. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application (2027-2032) Table 44. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2026) & (k units) Table 46. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2021-2026) Table 47. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2027-2032) & (k units) Table 48. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2027-2032) Table 49. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Region (2021-2026) Table 52. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Region (2027-2032) Table 54. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026) & (k units) Table 59. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2021-2026) Table 60. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032) & (k units) Table 61. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2027-2032) Table 62. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Market Share by Country (2021-2026) Table 64. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Market Share by Country (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 70. Novartis AG Recent Development Table 71. RXi Pharmaceuticals Corp Company Information Table 72. RXi Pharmaceuticals Corp Business Overview Table 73. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 75. RXi Pharmaceuticals Corp Recent Development Table 76. Promedior Inc Company Information Table 77. Promedior Inc Business Overview Table 78. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio Table 80. Promedior Inc Recent Development Table 81. Key Raw Materials Table 82. Raw Materials Key Suppliers Table 83. Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors List Table 84. Proliferative Vitreoretinopathy (PVR) Therapeutics Customers List Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Product Image Figure 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PRM-167 Image Figure 10. XOMA-089 Image Figure 11. Others Image Figure 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Type (2021-2032) Figure 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. ASCs Image Figure 21. Others Image Figure 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Application (2021-2032) Figure 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application (2021-2032) Figure 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • PRM-167
  • XOMA-089
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
  • Others
Companies covered
  • Novartis AG
  • RXi Pharmaceuticals Corp
  • Promedior Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Dynamics
  1. 2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
  2. 2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers
  3. 2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints
3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Company
  1. 3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Product Type and Application
  8. 3.8 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Proliferative Vitreoretinopathy (PVR) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
  1. 4.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Type Introduction
  2. 4.1.1 PRM-167
  3. 4.1.2 XOMA-089
  4. 4.1.3 Others
  5. 4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type
  6. 4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type
  10. 4.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Type (2021-2032)
  12. 4.3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type (2021-2032)
5 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
  1. 5.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.1.4 Others
  6. 5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application
  7. 5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application
  11. 5.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Application (2021-2032)
  13. 5.3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application (2021-2032)
6 Proliferative Vitreoretinopathy (PVR) Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Proliferative Vitreoretinopathy (PVR) Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 RXi Pharmaceuticals Corp
  8. 8.2.1 RXi Pharmaceuticals Corp Company Information
  9. 8.2.2 RXi Pharmaceuticals Corp Business Overview
  10. 8.2.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  12. 8.2.5 RXi Pharmaceuticals Corp Recent Developments
  13. 8.3 Promedior Inc
  14. 8.3.1 Promedior Inc Company Information
  15. 8.3.2 Promedior Inc Business Overview
  16. 8.3.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
  18. 8.3.5 Promedior Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Analysis
  2. 9.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Mode & Process
  6. 9.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
  9. 9.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst